Europe's High: Irish GPs Against Pot, Switzerland-Spain Share Data On Cannabis Clubs & More
Portfolio Pulse from Nina Zdinjak
Denmark's medical cannabis pilot trial has seen a 90% growth in patient enrollment over 12 months, making it the largest access scheme in the country. The Pilot Programme allows all doctors to prescribe any unlicensed medicines approved for trial. Jazz Pharmaceuticals' (NASDAQ:JAZZ) Sativex and Epidoloex are only allowed under the Pharmaceutical Scheme. In other news, Malta's Sprawt Chra violated advertising rules, Ireland's College of General Practitioners issued a statement opposing cannabis legalization, and Swiss public health professionals visited a Barcelona cannabis social club to exchange harm reduction strategies.
October 20, 2023 | 7:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Jazz Pharmaceuticals' products Sativex and Epidoloex are only allowed under Denmark's Pharmaceutical Scheme, which is one of the access schemes for medical marijuana in the country.
The news mentions Jazz Pharmaceuticals in the context of Denmark's medical marijuana schemes. While the company's products are included in one of the schemes, it's not the most popular one, which could limit their market penetration. However, the overall impact on the company's stock is uncertain as the news doesn't provide enough information about the size or profitability of this specific market for Jazz.
CONFIDENCE 80
IMPORTANCE 50
RELEVANCE 50